Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for acute GVHD prevention after haploidentical HSCT
NCT04688021Phase 2Unknown
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in graft-versus-host disease (GVHD). Primary endpoints: Cumulative incidence of grade II-IV acute graft-versus-host disease at 100 days and Cumulative incidence of non grade II-IV acute graft-versus-host disease survival at 100 days. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04688021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688021.